Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Voya Asia Pacific High Dividend Equity Income Fund
T.IAE
Primary Symbol:
IAE
Voya Asia Pacific High Dividend Equity Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund’s investment objective is total return through a combination of current income, capital gains and capital appreciation. The Fund seeks to achieve its investment objective by investing primarily in a portfolio of dividend yielding equity securities of Asia Pacific companies. The Fund will seek to achieve its investment objective by investing at least 80% of its managed assets in dividend producing equity securities of, or derivatives having economic characteristics similar to the equity securities of Asia Pacific Companies that are listed and traded principally on Asia Pacific exchanges. The Fund will invest in equity securities and will select securities through a bottom-up process that is based upon quantitative analysis. Voya Investments, LLC is an investment adviser of the Fund.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
NYSE:IAE - Post by User
Voya Asia Pacific High Dividend Equity Income Fund
> your not blind are you
<< Previous
Bullboard Posts
Next >>
(39)
•••
tannin
X
View Profile
View Bullboard History
Comment by
tannin
on Feb 08, 2017 3:02pm
190 Views
Post# 25818233
RE:your not blind are you
RE:your not blind are you
swale, this 'retard' has been buying/trading IAE since 1st., '08 buy at 20 cents ...highly profitably. Imo, Delek is agnostic, buy cheap or sell expensive...could be 20% more here
Comment on this Post
<< Previous
Bullboard Posts
Next >>
A potential breakthrough in spinal cord and optic nerve injury treatment
Eminent acquires promising Nevada gold project
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide
NervGen Pharma: Proof that NVG-291 works?
Invest wiser with BMO's InvestorLine Platform features
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.
Growth Rocket 2025 – Why dynaCERT is in the Spotlight